Çukurova University

InfanDx AG: Clinical Findings from Prospective AAMBI Study Highlight Need for Better Early Detection of Neonatal Brain Injury

Retrieved on: 
Thursday, February 10, 2022
Çukurova University, HIE, Biomarker, University of Tübingen, Education, Hypoxia (medical), Conference, Solution, Â, Cerebral palsy, Company, German, University of Bonn, Poster, Risk, EEG, Nerve, University, Amplitude, Adana, Classification, Blood, Federal Ministry of Health (Germany), CEO, Critical care, VO2 max, APGAR, BMBF, Epilepsy, Government budget balance, Laboratory, MRI, Pharmaceutical industry, Medical imaging, Medical device, Research

The data highlight the need for novel reliable biomarkers for the early detection of Hypoxic-Ischemic Encephalopathy (HIE), i.e., neural injury caused by oxygen deprivation around the time of birth (perinatal asphyxia).

Key Points: 
  • The data highlight the need for novel reliable biomarkers for the early detection of Hypoxic-Ischemic Encephalopathy (HIE), i.e., neural injury caused by oxygen deprivation around the time of birth (perinatal asphyxia).
  • The AAMBI study was conducted as a prospective observational trial at four neonatal centers in Turkey.
  • The neonatal short-term clinical outcome was determined for 144 surviving children based on further clinical assessment, cerebral MRI and amplitude-integrated EEG (aEEG).
  • Building on AAMBI and further clinical studies, InfanDx is developing the HypoxE Test for the detection of early biomarkers for HIE in blood.

Immunicom Recruits Dr. Erdal Bozdoğan to Join Leadership Team

Retrieved on: 
Tuesday, December 14, 2021
Technology, Research, Other Technology, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, FDA, Eli Lilly, Company, Eli Lilly and Company, Cancer, Oncology, Çukurova University, Abbott Laboratories, TNBC, General manager, Marketing, Osteoporosis, Strategic planning, CE marking, Degenerative disease, Takeda, Technology, Pharmaceutical industry, Nutricia

Immunicom, Inc. , a clinical-stage biotech pioneering non-pharmaceutical immunotherapies, announced that Dr. Erdal Bozdoan has joined Immunicom as the companys General Manager in Turkey.

Key Points: 
  • Immunicom, Inc. , a clinical-stage biotech pioneering non-pharmaceutical immunotherapies, announced that Dr. Erdal Bozdoan has joined Immunicom as the companys General Manager in Turkey.
  • Dr. Bozdoan is known both for his track record of successful development and implementation of commercial strategies for international and regional product launches, and for his exceptional operational leadership skills.
  • Dr. Bozdoan previously served as General Manager at Takeda Pharmaceuticals Turkey, where he achieved excellent results while managing the marketing and commercialization strategy for Takedas oncology and specialty-care franchise in Turkey.
  • Experiencing the Immunicom teams tremendous enthusiasm and excitement for its groundbreaking work in the field of subtractive cancer therapy makes joining this team an incredible opportunity.